

Harm potential of magic mushroom use: A review

Regulatory Toxicology and Pharmacology

59, 423-429

DOI: [10.1016/j.yrtph.2011.01.006](https://doi.org/10.1016/j.yrtph.2011.01.006)

Citation Report

#	ARTICLE	IF	CITATIONS
3	A fatal case of "magic mushroom"™ ingestion in a heart transplant recipient. <i>Internal Medicine Journal</i> , 2012, 42, 1268-1269.	0.5	30
5	Risk assessment of gamma-hydroxybutyric acid (GHB) in the Netherlands. <i>Regulatory Toxicology and Pharmacology</i> , 2012, 63, 55-63.	1.3	23
6	Mushrooms. , 2013, , 659-676.		2
7	Natural Product (Fungal and Herbal) Novel Psychoactive Substances. , 2013, , 345-362.		8
8	Magic truffles or Philosopher's stones: a legal way to sell psilocybin?. <i>Drug Testing and Analysis</i> , 2013, 5, 182-185.	1.6	11
9	Fungal Hallucinogens Psilocin, Ibotenic Acid, and Muscimol. <i>Therapeutic Drug Monitoring</i> , 2013, 35, 420-442.	1.0	49
10	The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs. <i>Frontiers in Human Neuroscience</i> , 2014, 8, 20.	1.0	673
11	Potential Therapeutic Effects of Psilocybin/Psilocin are Minimized While Possible Adverse Reactions are Overrated. <i>Therapeutic Drug Monitoring</i> , 2014, 36, 131-132.	1.0	4
12	Alternative Drugs of Abuse. <i>Clinical Reviews in Allergy and Immunology</i> , 2014, 46, 3-18.	2.9	15
13	Psilocybin " Summary of knowledge and new perspectives. <i>European Neuropsychopharmacology</i> , 2014, 24, 342-356.	0.3	167
15	User perceptions of mental health consequences of hallucinogen use in self-identified spiritual contexts. <i>NAD Nordic Studies on Alcohol and Drugs</i> , 2015, 32, 545-562.	0.7	4
16	Legal highs: staying on top of the flood of novel psychoactive substances. <i>Therapeutic Advances in Psychopharmacology</i> , 2015, 5, 97-132.	1.2	136
17	Bioactive Alkaloids of Hallucinogenic Mushrooms. <i>Studies in Natural Products Chemistry</i> , 2015, , 133-168.	0.8	15
18	Mechanisms of Action and Persistent Neuroplasticity by Drugs of Abuse. <i>Pharmacological Reviews</i> , 2015, 67, 872-1004.	7.1	125
19	The Legal Highs of Novel Drugs of Abuse. <i>Journal of Drug Abuse</i> , 2016, 02, .	0.2	3
20	Back to the future: Research renewed on the clinical utility of psychedelic drugs. <i>Journal of Psychopharmacology</i> , 2016, 30, 1198-1200.	2.0	7
21	Clinical applications of hallucinogens: A review.. <i>Experimental and Clinical Psychopharmacology</i> , 2016, 24, 229-268.	1.3	130
22	Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. <i>Journal of Psychopharmacology</i> , 2016, 30, 1268-1278.	2.0	303

#	ARTICLE	IF	CITATIONS
23	Psilocybin as an Inducer of Ego Death and Similar Experiences of Religious Provenance. , 2016, , 875-889.		0
24	Assays for Detection of Fungal Hallucinogens Such as Psilocybin and Psilocin. , 2016, , 909-926.		3
25	Multivariate optimization of the hollow fibre liquid phase microextraction of muscimol in human urine samples. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2016, 1033-1034, 372-381.	1.2	11
26	Classical hallucinogens and neuroimaging: A systematic review of human studies. <i>Neuroscience and Biobehavioral Reviews</i> , 2016, 71, 715-728.	2.9	79
27	Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years. <i>Therapeutic Advances in Psychopharmacology</i> , 2016, 6, 193-213.	1.2	204
28	Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance. <i>Drug Metabolism Reviews</i> , 2017, 49, 84-91.	1.5	123
29	Ayahuasca, dimethyltryptamine, and psychosis: a systematic review of human studies. <i>Therapeutic Advances in Psychopharmacology</i> , 2017, 7, 141-157.	1.2	115
30	New psychoactive substances of natural origin: A brief review. <i>Journal of Food and Drug Analysis</i> , 2017, 25, 461-471.	0.9	60
32	Clinical potential of psilocybin as a treatment for mental health conditions. <i>Mental Health Clinician</i> , 2017, 7, 24-28.	0.5	36
33	A role for enhanced functions of sleep in psychedelic therapy?. <i>Adaptive Behavior</i> , 2018, 26, 129-135.	1.1	7
34	A Global Overview of Edible Mushrooms. <i>Fungal Biology</i> , 2018, , 15-56.	0.3	7
36	The Varieties of the Psychedelic Experience: A Preliminary Study of the Association Between the Reported Subjective Effects and the Binding Affinity Profiles of Substituted Phenethylamines and Tryptamines. <i>Frontiers in Integrative Neuroscience</i> , 2018, 12, 54.	1.0	51
37	Does getting high hurt? Characterization of cases of LSD and psilocybin-containing mushroom exposures to national poison centers between 2000 and 2016. <i>Journal of Psychopharmacology</i> , 2018, 32, 1286-1294.	2.0	61
38	Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development. <i>Frontiers in Pharmacology</i> , 2018, 9, 733.	1.6	115
39	Toxicity Assessment of Wild Mushrooms from the Western Ghats, India: An in Vitro and Sub-Acute in Vivo Study. <i>Frontiers in Pharmacology</i> , 2018, 9, 90.	1.6	11
40	The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. <i>Neuropharmacology</i> , 2018, 142, 143-166.	2.0	184
41	Pharmacokinetic and Pharmacodynamic Aspects of Peyote and Mescaline: Clinical and Forensic Repercussions. <i>Current Molecular Pharmacology</i> , 2019, 12, 184-194.	0.7	57
42	Psychedelic microdosing benefits and challenges: an empirical codebook. <i>Harm Reduction Journal</i> , 2019, 16, 43.	1.3	59

#	ARTICLE	IF	CITATIONS
43	Microdosing psychedelics: More questions than answers? An overview and suggestions for future research. <i>Journal of Psychopharmacology</i> , 2019, 33, 1039-1057.	2.0	121
44	Prediction of Human Lethality of Psychoactive Drugs From Rodent LD50 Values. <i>International Journal of Quantitative Structure-Property Relationships</i> , 2019, 4, 1-27.	1.1	1
45	Descriptive assemblage of psychedelic microdosing: Netnographic study of Youtubeâ„¢ videos and on-going research projects. <i>Performance Enhancement and Health</i> , 2019, 6, 129-138.	0.8	17
46	Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat. <i>Scientific Reports</i> , 2019, 9, 14914.	1.6	79
47	Microdosing psychedelics: personality, mental health, and creativity differences in microdosers. <i>Psychopharmacology</i> , 2019, 236, 731-740.	1.5	104
48	Mushroom poisoning: A proposed new clinical classification. <i>Toxicon</i> , 2019, 157, 53-65.	0.8	105
49	Acute renal injury cause by confirmed <i>Psilocybe cubensis</i> mushroom ingestion. <i>Medical Mycology Case Reports</i> , 2019, 23, 55-57.	0.7	9
50	Unpredictable Behavior Under the Influence of "Magic Mushrooms": A Case Report and Review of the Literature. <i>Journal of Forensic Sciences</i> , 2019, 64, 1266-1270.	0.9	17
51	Patterns of use, desired effects, and mental health status of a sample of natural psychoactive drug users. <i>Drugs: Education, Prevention and Policy</i> , 2020, 27, 191-198.	0.8	10
52	Biomedical analysis of New Psychoactive Substances (NPS) of natural origin. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020, 179, 112945.	1.4	31
53	Therapeutic Use of LSD in Psychiatry: A Systematic Review of Randomized-Controlled Clinical Trials. <i>Frontiers in Psychiatry</i> , 2019, 10, 943.	1.3	80
54	Neuropharmacological modulation of the aberrant bodily self through psychedelics. <i>Neuroscience and Biobehavioral Reviews</i> , 2020, 108, 526-541.	2.9	37
55	Perceived harm, motivations for use and subjective experiences of recreational psychedelic "magic"™ mushroom use. <i>Journal of Psychopharmacology</i> , 2020, 34, 999-1007.	2.0	9
56	Phytochemical, Cytotoxicity, Antioxidant and Anti-Inflammatory Effects of <i>Psilocybe Natalensis</i> Magic Mushroom. <i>Plants</i> , 2020, 9, 1127.	1.6	26
57	The potential synergistic effects between psychedelic administration and nature contact for the improvement of mental health. <i>Health Psychology Open</i> , 2020, 7, 205510292097812.	0.7	32
59	Hallucinogenic mushroom misuse reported to Texas poison centers. <i>Journal of Addictive Diseases</i> , 2020, 38, 482-488.	0.8	3
60	Self-reported negative outcomes of psilocybin users: A quantitative textual analysis. <i>PLoS ONE</i> , 2020, 15, e0229067.	1.1	36
61	The Viability of Microdosing Psychedelics as a Strategy to Enhance Cognition and Well-being - An Early Review. <i>Journal of Psychoactive Drugs</i> , 2020, 52, 300-308.	1.0	13

#	ARTICLE	IF	CITATIONS
62	A "Trip" to the Intensive Care Unit: An Intravenous Injection of Psilocybin. <i>Journal of the Academy of Consultation-Liaison Psychiatry</i> , 2021, 62, 370-371.	0.2	6
63	Peculiar plants and fantastic fungi: An ethnobotanical study of the use of hallucinogenic plants and mushrooms in Slovenia. <i>PLoS ONE</i> , 2021, 16, e0245022.	1.1	6
64	Effectiveness of Psilocybin on Depression: A Qualitative Study. <i>Electronic Journal of General Medicine</i> , 2021, 18, em296.	0.3	5
66	Use of psilocybin ("mushrooms") among US adults: 2015–2018. <i>Journal of Psychedelic Studies</i> , 2021, 5, 17-21.	0.5	34
67	The Therapeutic Potential of Psilocybin. <i>Molecules</i> , 2021, 26, 2948.	1.7	78
69	Anti-Inflammatory Effects of Four Psilocybin-Containing Magic Mushroom Water Extracts in vitro on 15-Lipoxygenase Activity and on Lipopolysaccharide-Induced Cyclooxygenase-2 and Inflammatory Cytokines in Human U937 Macrophage Cells. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 3729-3738.	1.6	26
70	Testing human hair after magic mushrooms abuse by LC-MS/MS: pitfalls and limitations. <i>Forensic Chemistry</i> , 2021, 26, 100364.	1.7	0
72	Evaluating the risk of psilocybin for the treatment of bipolar depression: A review of the research literature and published case studies. <i>Journal of Affective Disorders Reports</i> , 2021, 6, 100240.	0.9	13
73	Rediscovering Psilocybin as an Antidepressive Treatment Strategy. <i>Pharmaceuticals</i> , 2021, 14, 985.	1.7	8
74	Psychedelics, Sociality, and Human Evolution. <i>Frontiers in Psychology</i> , 2021, 12, 729425.	1.1	27
75	Dose effect of psilocybin on primary and secondary depression: a preliminary systematic review and meta-analysis. <i>Journal of Affective Disorders</i> , 2022, 296, 26-34.	2.0	29
76	Effects and safety of <i>Psilocybe cubensis</i> and <i>Panaeolus cyanescens</i> magic mushroom extracts on endothelin-1-induced hypertrophy and cell injury in cardiomyocytes. <i>Scientific Reports</i> , 2020, 10, 22314.	1.6	15
77	Management of pharmaceutical and recreational drug poisoning. <i>Annals of Intensive Care</i> , 2020, 10, 157.	2.2	40
78	Psychedelics and Mental Health: A Population Study. <i>PLoS ONE</i> , 2013, 8, e63972.	1.1	239
79	Review and Recommendations for Drug Testing in Substance Use Treatment Contexts. , 2016, 2, .		8
80	Psychedelics as Medicines for Substance Abuse Rehabilitation: Evaluating Treatments with LSD, Peyote, Ibogaine and Ayahuasca. <i>Current Drug Abuse Reviews</i> , 2015, 7, 101-116.	3.4	72
81	Psychedelic therapy: a roadmap for wider acceptance and utilization. <i>Nature Medicine</i> , 2021, 27, 1669-1671.	15.2	25
82	Indole Hallucinogens. , 2016, , 1-22.		1

#	ARTICLE	IF	CITATIONS
83	Hallucinogens. , 2017, , 1587-1607.		0
84	Microbiological Quality of Eight Wild Edible Mushroom Species from Turkey. Celal Bayar Universitesi Fen Bilimleri Dergisi, 0, , .	0.1	1
86	Preventing and Managing Risk of Violence and Suicide in Substance-Abusing Patients in the Emergency Department. Current Clinical Psychiatry, 2019, , 163-183.	0.2	0
87	Hallucinogen-Related Disorders. Psychiatry Update, 2022, , 41-56.	0.1	0
88	Psychedelics and Hallucinogens in Psychiatry: Finding New Pharmacological Targets. Current Topics in Medicinal Chemistry, 2022, 22, 1250-1260.	1.0	3
89	Knowledge and Use of Novel Psychoactive Substances in an Italian Sample with Substance Use Disorders. International Journal of Environmental Research and Public Health, 2022, 19, 915.	1.2	2
90	Adverse effects of psychedelics: From anecdotes and misinformation to systematic science. Journal of Psychopharmacology, 2022, 36, 258-272.	2.0	103
91	Psilocybin for Treating Psychiatric Disorders: A Psychonaut Legend or a Promising Therapeutic Perspective?. Journal of Xenobiotics, 2022, 12, 41-52.	2.9	10
92	Diversity, biology, and history of psilocybin-containing fungi: Suggestions for research and technological development. Fungal Biology, 2022, 126, 308-319.	1.1	32
93	The Acceptance/Avoidance-Promoting Experiences Questionnaire (APEQ): A theory-based approach to psychedelic drugsâ€™ effects on psychological flexibility. Journal of Psychopharmacology, 2022, 36, 387-408.	2.0	19
94	Magic Mushroom Use: A Qualitative Interview Study of Post-Trip Impacts and Strategies for Optimizing Experiences. Journal of Psychoactive Drugs, 2023, 55, 151-158.	1.0	4
95	Recent advances in the psychopharmacology of major depressive disorder. BJ Psych Advances, 2023, 29, 117-130.	0.5	2
96	Adverse experiences resulting in emergency medical treatment seeking following the use of magic mushrooms. Journal of Psychopharmacology, 2022, 36, 965-973.	2.0	22
111	An Overview on the Taxonomy, Phylogenetics and Ecology of the Psychedelic Genera Psilocybe, Panaeolus, Pluteus and Gymnopilus. Frontiers in Forests and Global Change, 2022, 5, .	1.0	10
112	Psilocybin for Trauma-Related Disorders. Current Topics in Behavioral Neurosciences, 2022, , 319-332.	0.8	7
114	Three Naturally-Occurring Psychedelics and Their Significance in the Treatment of Mental Health Disorders. Frontiers in Pharmacology, 0, 13, .	1.6	2
116	Are you tripping comfortably? Investigating the relationship between harm reduction and the psychedelic experience. Harm Reduction Journal, 2022, 19, .	1.3	2
117	The Use of Psychedelics in the Treatment of Medical Conditions: An Analysis of Currently Registered Psychedelics Studies in the American Drug Trial Registry. Cureus, 2022, , .	0.2	7

#	ARTICLE	IF	CITATIONS
118	Hallucinogenic Drugs. , 2022, , 267-298.		0
119	Psilocybin and Magic Mushrooms: Patterns of Abuse and Consequences of Recreational Misuse. , 2022, , 2427-2455.		0
120	Psilocybin containing mushrooms: a rapidly developing biotechnology industry in the psychiatry, biomedical and nutraceutical fields. 3 Biotech, 2022, 12, .	1.1	2
121	Mushrooms, psilocybin. , 2024, , 567-569.		0
122	The Varieties of Psychedelic Law. SSRN Electronic Journal, 0, , .	0.4	0
123	Matrix-assisted laser-desorption/ionizationâ€“mass spectrometric imaging of psilocybin and its analogues in psychedelic mushrooms using a cesium chloride-coated target plate. Analytical and Bioanalytical Chemistry, 0, , .	1.9	0
124	Therapeutic uses of psychedelics for eating disorders and body dysmorphic disorder. Journal of Psychopharmacology, 2023, 37, 3-13.	2.0	3
125	The varieties of psychedelic law. Neuropharmacology, 2023, 226, 109399.	2.0	9
126	Novel Perspective of Medicinal Mushroom Cultivations: A Review Case for â€“Magicâ€™ Mushrooms. Agronomy, 2022, 12, 3185.	1.3	7
127	Psilocin suppresses methamphetamineâ€“induced hyperlocomotion and acquisition of conditioned place preference via <sc>D2R</sc> â€“mediated <sc>ERK</sc> signaling. CNS Neuroscience and Therapeutics, 0, , .	1.9	3
128	Hofmann vs. Paracelsus: Do Psychedelics Defy the Basics of Toxicology?â€“A Systematic Review of the Main Ergolamines, Simple Tryptamines, and Phenylethylamines. Toxics, 2023, 11, 148.	1.6	3
129	Experiences of psilocybin treatment for clinical conditions: A qualitative metaâ€“synthesis. International Journal of Mental Health Nursing, 2023, 32, 1025-1037.	2.1	4
130	Ethical and Practical Considerations for the Use of Psychedelics in Psychiatry. Psychiatric Services, 2023, 74, 838-846.	1.1	17
131	Commentary: Evidence-Informed Recommendation to Achieve Approximate Parity in the Allowed Number of Doses for Common Psychedelics. Journal of Psychoactive Drugs, 0, , 1-5.	1.0	1